Literature DB >> 24393804

Ramosetron in irritable bowel syndrome with diarrhea: new hope or the same old story?

Madhusudan Grover1, Michael Camilleri1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24393804      PMCID： PMC4032610          DOI： 10.1016/j.cgh.2013.12.025

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN： 1542-3565            Impact factor:   11.382


× No keyword cloud information.
  28 in total

Review 1.  The risk of ischaemic colitis in irritable bowel syndrome patients treated with serotonergic therapies.

Authors:  James H Lewis
Journal:  Drug Saf       Date:  2011-07-01       Impact factor: 5.606

2.  Effect of ramosetron on stool consistency in male patients with irritable bowel syndrome with diarrhea.

Authors:  Shin Fukudo; Motoko Ida; Hiraku Akiho; Yoshihiro Nakashima; Kei Matsueda
Journal:  Clin Gastroenterol Hepatol       Date:  2013-12-04       Impact factor: 11.382

3.  Role of the serotonin3 receptor in stress-induced defecation.

Authors:  K Miyata; T Kamato; A Nishida; H Ito; H Yuki; M Yamano; R Tsutsumi; Y Katsuyama; K Honda
Journal:  J Pharmacol Exp Ther       Date:  1992-04       Impact factor: 4.030

4.  GR 38032F (ondansetron), a selective 5HT3 receptor antagonist, slows colonic transit in healthy man.

Authors:  N J Talley; S F Phillips; A Haddad; L J Miller; C Twomey; A R Zinsmeister; R L MacCarty; A Ciociola
Journal:  Dig Dis Sci       Date:  1990-04       Impact factor: 3.199

5.  Differential 5-HT3 mediation of human gastrocolonic response and colonic peristaltic reflex.

Authors:  E S Björnsson; W D Chey; U Ladabaum; M L Woods; F G Hooper; C Owyang; W L Hasler
Journal:  Am J Physiol       Date:  1998-09

6.  Involvement of the 5-HT3 receptor in CRH-induce defecation in rats.

Authors:  K Miyata; H Ito; S Fukudo
Journal:  Am J Physiol       Date:  1998-05

7.  Reduction of rectal sensitivity and post-prandial motility by granisetron, a 5 HT3-receptor antagonist, in patients with irritable bowel syndrome.

Authors:  A Prior; N W Read
Journal:  Aliment Pharmacol Ther       Date:  1993-04       Impact factor: 8.171

8.  Medium-term effects of a new 5HT3 antagonist, alosetron, in patients with carcinoid diarrhoea.

Authors:  S B Saslow; J S Scolapio; M Camilleri; L A Forstrom; G M Thomforde; D D Burton; J Rubin; H C Pitot; A R Zinsmeister
Journal:  Gut       Date:  1998-05       Impact factor: 23.059

Review 9.  Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Viola Andresen; Victor M Montori; Jutta Keller; Colin P West; Peter Layer; Michael Camilleri
Journal:  Clin Gastroenterol Hepatol       Date:  2008-01-31       Impact factor: 11.382

10.  Randomised clinical trial: alosetron improves quality of life and reduces restriction of daily activities in women with severe diarrhoea-predominant IBS.

Authors:  F Cremonini; J P Nicandro; V Atkinson; R Shringarpure; E Chuang; A Lembo
Journal:  Aliment Pharmacol Ther       Date:  2012-07-10       Impact factor: 8.171
View more
  6 in total

Review 1.  Novel therapeutic agents in neurogastroenterology: advances in the past year.

Authors:  M Camilleri
Journal:  Neurogastroenterol Motil       Date:  2014-06-23       Impact factor: 3.598

2.  5-HT3 receptor signaling in serotonin transporter-knockout rats: a female sex-specific animal model of visceral hypersensitivity.

Authors:  Nadine El-Ayache; James J Galligan
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2018-10-25       Impact factor: 4.052

3.  Effect of ramosetron in female patients with irritable bowel syndrome with diarrhea: a phase III long-term study.

Authors:  Shin Fukudo; Yoshikazu Kinoshita; Toshikatsu Okumura; Motoko Ida; Kenta Hayashi; Hiraku Akiho; Yoshihiro Nakashima; Ken Haruma
Journal:  J Gastroenterol       Date:  2016-01-22       Impact factor: 7.527

Review 4.  Efficacy and safety of 5-hydroxytryptamine 3 receptor antagonists in irritable bowel syndrome: A systematic review and meta-analysis of randomized controlled trials.

Authors:  Yongping Zheng; Ting Yu; Yurong Tang; Wenjie Xiong; Xiaoxue Shen; Ling Jiang; Lin Lin
Journal:  PLoS One       Date:  2017-03-14       Impact factor: 3.240

5.  Evaluation of the gastrointestinal anti-motility effect of Anacardium occidentale stem bark extract: A mechanistic study of antidiarrheal activity.

Authors:  Blessing O Omolaso; Francis S Oluwole; Olugbenga A Odukanmi; Julius K Adesanwo; Ahmed A Ishola; Kayode E Adewole
Journal:  J Pharm Anal       Date:  2020-07-21

Review 6.  Pharmacologic Agents for Chronic Diarrhea.

Authors:  Kwang Jae Lee
Journal:  Intest Res       Date:  2015-10-15
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.